Heartflow's AI Plaque Analysis software leads to significant improvements in cholesterol management and cardiac risk reduction in coronary artery disease patients.
Key Details
- 1DECIDE Registry, the largest prospective study of its kind, enrolled ~20,000 CAD patients at 30+ US clinical sites.
- 2Heartflow AI Plaque Analysis prompted treatment changes in over 50% of patients versus CCTA alone.
- 3Patients managed using the software saw mean LDL cholesterol reductions of 18.7 mg/dL.
- 4A 15% estimated reduction in cardiac event risk was observed for these patients.
- 5Significant management changes occurred even in patients with no calcified plaque.
- 6The AI provides individualized risk insights by quantifying and characterizing all plaque types, including non-calcified, soft plaques.
Why It Matters
This large-scale prospective evidence demonstrates that adding AI-based plaque quantification to CCTA can materially change patient management, with potential to reduce adverse cardiac events. These results highlight the growing role of imaging AI in personalizing cardiovascular care.
Source
Cardiovascular Business
Related News
•Cardiovascular Business
Former US Surgeon General Jerome Adams Joins Eko as Medical Advisor
Former US Surgeon General Jerome Adams has joined Eko Health as a distinguished medical advisor to support AI-powered cardiac and pulmonary detection technologies.
•AuntMinnie
Habitat AI Model Improves Risk Stratification of Lung Nodules on LDCT
A 'habitat' AI model outperforms standard 2D approaches in stratifying lung adenocarcinoma risk in subsolid nodules on low-dose CT scans.
•AuntMinnie
AI Model Uses Chest CT to Diagnose and Grade COPD Severity
A machine learning model based on chest CT images accurately diagnoses and grades the severity of COPD.